Johan Liwing

638 total citations
35 papers, 411 citations indexed

About

Johan Liwing is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Johan Liwing has authored 35 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 10 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in Johan Liwing's work include Multiple Myeloma Research and Treatments (16 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer Treatment and Pharmacology (5 papers). Johan Liwing is often cited by papers focused on Multiple Myeloma Research and Treatments (16 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer Treatment and Pharmacology (5 papers). Johan Liwing collaborates with scholars based in Sweden, United States and United Kingdom. Johan Liwing's co-authors include Teresia Nyman, Wilhelmus Johannes Andreas Grooten, Christina Wiktorin, J Aschan, Hareth Nahi, Frida Schain, Gösta Gahrton, Evren Alici, Johan Lund and John Hornberger and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Johan Liwing

32 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Johan Liwing Sweden 11 161 144 103 90 60 35 411
Gabriel Tremblay United States 12 124 0.8× 8 0.1× 84 0.8× 107 1.2× 74 1.2× 84 425
M Zucchella Italy 9 102 0.6× 24 0.2× 47 0.5× 77 0.9× 20 0.3× 15 332
Susan Robson Switzerland 7 50 0.3× 13 0.1× 115 1.1× 129 1.4× 135 2.3× 17 826
Shawgi Sukumaran Australia 11 39 0.2× 23 0.2× 133 1.3× 208 2.3× 60 1.0× 44 407
Michael Steinberg United States 12 197 1.2× 14 0.1× 97 0.9× 141 1.6× 44 0.7× 21 476
Mairead MacKenzie United Kingdom 9 40 0.2× 60 0.4× 38 0.4× 78 0.9× 30 0.5× 26 296
Charlene M. McShane United Kingdom 9 76 0.5× 30 0.2× 85 0.8× 67 0.7× 41 0.7× 27 326
Beng Fuh United States 11 233 1.4× 15 0.1× 98 1.0× 89 1.0× 40 0.7× 30 512
Brian Bekker Hansen Denmark 13 25 0.2× 28 0.2× 118 1.1× 20 0.2× 33 0.6× 20 441
Naresh Bellam United States 7 14 0.1× 20 0.1× 201 2.0× 161 1.8× 26 0.4× 12 457

Countries citing papers authored by Johan Liwing

Since Specialization
Citations

This map shows the geographic impact of Johan Liwing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan Liwing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan Liwing more than expected).

Fields of papers citing papers by Johan Liwing

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Johan Liwing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan Liwing. The network helps show where Johan Liwing may publish in the future.

Co-authorship network of co-authors of Johan Liwing

This figure shows the co-authorship network connecting the top 25 collaborators of Johan Liwing. A scholar is included among the top collaborators of Johan Liwing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Johan Liwing. Johan Liwing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khosla, Sajan, et al.. (2021). The Alignment of Real-World Evidence and Digital Health: Realising the Opportunity. Therapeutic Innovation & Regulatory Science. 55(4). 889–898. 11 indexed citations
2.
LoCasale, Robert, Chris L. Pashos, Nancy A Dreyer, et al.. (2020). Correction to: Bridging the Gap Between RCTs and RWE Through Endpoint Selection. Therapeutic Innovation & Regulatory Science. 55(1). 97–97. 1 indexed citations
3.
Schain, Frida, et al.. (2020). Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease. The European Journal of Health Economics. 22(1). 169–180. 11 indexed citations
4.
LoCasale, Robert, Chris L. Pashos, Nancy A Dreyer, et al.. (2020). Bridging the Gap Between RCTs and RWE Through Endpoint Selection. Therapeutic Innovation & Regulatory Science. 55(1). 90–96. 10 indexed citations
5.
Aly, Markus, Mahmoud Hashim, Bart Heeg, et al.. (2018). Time-to-event Outcomes in Men with Nonmetastatic Castrate-resistant Prostate Cancer—A Systematic Literature Review and Pooling of Individual Participant Data. European Urology Focus. 5(5). 788–798. 6 indexed citations
6.
Liwing, Johan, et al.. (2017). Estimates of PFS, TTNT Per Treatment Line and their Relationship for Multiple Myeloma Patients. Value in Health. 20(9). A548–A548. 1 indexed citations
7.
8.
Grövdal, Michael, Hareth Nahi, Gösta Gahrton, et al.. (2015). Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT. Bone Marrow Transplantation. 50(6). 808–812. 30 indexed citations
9.
Heeg, Bart, Michel van Agthoven, Johan Liwing, et al.. (2014). Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT). Value in Health. 17(7). A617–A618. 2 indexed citations
10.
Uttervall, Katarina, Adil Doganay Duru, Johan Lund, et al.. (2014). The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment. PLoS ONE. 9(7). e101819–e101819. 42 indexed citations
11.
12.
Lund, Johan, Katarina Uttervall, Johan Liwing, et al.. (2013). Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma – a retrospective population based study of 1162 patients. European Journal Of Haematology. 92(1). 19–25. 4 indexed citations
13.
El‐Serafi, Ibrahim, et al.. (2013). Comparison of Algorithms for Oral Busulphan Area Under the Concentration–Time Curve Limited Sampling Estimate. Clinical Drug Investigation. 34(1). 43–52. 4 indexed citations
14.
15.
Uttervall, Katarina, Johan O. L. Andreasson, Johan Liwing, et al.. (2012). Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients. Blood. 120(21). 5033–5033. 2 indexed citations
16.
Heeg, Bart, Michel van Agthoven, Johan Liwing, et al.. (2010). Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach. Blood. 116(21). 3046–3046. 4 indexed citations
17.
Liwing, Johan, Ingmar Sandberg, J Aschan, et al.. (2009). PCN86 THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA—A NORDIC COMPARISON. Value in Health. 12(7). A273–A273. 2 indexed citations
18.
Hedenus, Michael, et al.. (2008). Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. Journal of Clinical Pharmacy and Therapeutics. 33(4). 365–374. 12 indexed citations
19.
Nyman, Teresia, et al.. (2006). Sickness absence and concurrent low back and neck–shoulder pain: results from the MUSIC-Norrtälje study. European Spine Journal. 16(5). 631–638. 69 indexed citations
20.
Nyman, Teresia, et al.. (2006). Sickness absence and concurrent low back and neck–shoulder pain: results from the MUSIC-Norrtälje study. European Spine Journal. 16(5). 639–640. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriel Tremblay Breakdown of academic impact, for papers by M Zucchella Breakdown of academic impact, for papers by Susan Robson Breakdown of academic impact, for papers by Shawgi Sukumaran Breakdown of academic impact, for papers by Michael Steinberg Breakdown of academic impact, for papers by Mairead MacKenzie Breakdown of academic impact, for papers by Charlene M. McShane Breakdown of academic impact, for papers by Beng Fuh Breakdown of academic impact, for papers by Brian Bekker Hansen Breakdown of academic impact, for papers by Naresh Bellam
Rankless by CCL
2026